Pegasystems Inc
Change company Symbol lookup
Select an option...
PEGA Pegasystems Inc
NDRA ENDRA Life Sciences Inc
HIG-G Hartford Financial Services Group Inc
NLLSY Nel ASA
AHEXY Adecco Group AG
RIOCF RioCan Real Estate Investment Trust
RIO Rio Tinto PLC
RIG Transocean Ltd
RHHBY Roche Holding AG
RGP Resources Connection Inc
Go

Information Technology : Software | Mid Cap Growth
Company profile

Pegasystems Inc. develops, markets, licenses and supports software applications for marketing, sales and onboarding, and customer service needs. The Company also offers software applications built on the Pega platform. Its software is designed to assist clients in building, deploying and evolving enterprise applications. Its applications and platform intersect with and encompass several traditional software markets, including Customer Relationship Management (CRM); Business Process Management (BPM); Business Rules Management Systems (BRMS); Dynamic Case Management (DCM); Decision Management, which includes Predictive and Adaptive analytics, and the Vertical Specific Software (VSS) market of industry solutions and packaged applications. It provides implementation, consulting, training, technical support and hosting services to facilitate the use of its software. The Company offers real-time speech analytics solution powered by artificial intelligence (AI) for customer service teams.

Closing Price
$97.35
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
346,311
0

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Dicerna Pharmaceuticals, Inc. Corporation (Nasdaq - DRNA), Rogers Corporation (NYSE - ROG), Independence Holding Company (NYSE - IHC)

5:02 pm ET November 22, 2021 (Accesswire) Print

BALA CYNWYD, PA / ACCESSWIRE / November 22, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or calling toll free 855-576-4847. There is no cost or financial obligation to you.

Rogers Corporation (NYSE:ROG)

Under the terms of the merger agreement, Dupont will pay Rogers shareholders will receive $277.00 per share in cash for each share of Rogers stock they own. The investigation concerns whether the Rogers Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Dupont is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/rogers-corporation-nyse-rog/, or call 855-576-4847. No cost or obligation to you.

Independence Holding Company (NYSE:IHC)

Under the terms of the merger agreement, Geneve Holdings will acquire all outstanding shares of IHC common stock for $57.00 per share in an all-cash transaction. The investigation concerns whether the IHC Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Geneve Holdings is paying too little for the Company.

Additional information can be found at visit https://www.brodskysmith.com/cases/independence-holding-company-nyse-ihc/, or call 855-576-4847. No cost or obligation to you.

Dicerna Pharmaceuticals, Inc. Corporation (Nasdaq:DRNA)

Under the terms of the merger agreement, Dicerna will be acquired by Novo Nordisk, in an all-cash transaction with a total value of approximately $3.3 billion. Dicerna stockholders will receive $38.25 in cash for each share of Dicerna common stock they own.

The investigation concerns whether the Dicerna Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Novo Nordisk is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/dicerna-pharmaceuticals-inc-corporation-nasdaq-drna/, or call 855-576-4847. No cost or obligation to you.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

View source version on accesswire.com: https://www.accesswire.com/674215/NOTICE--IMPORTANT-SHAREHOLDER-INVESTIGATION-UPDATE-Brodsky-Smith-Reminds-Investors-of-Investigations-Related-to-the-Following-Companies-Dicerna-Pharmaceuticals-Inc-Corporation-Nasdaq-DRNA-Rogers-Corporation-NYSE--ROG-Independence-Holding

comtex tracking

COMTEX_397470887/2457/2021-11-22T17:02:32

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.